Drug Profile
Research programme: myometrial disorders and glaucoma therapeutics - Asterand
Alternative Names: PGN1473; R65 programme - AsterandLatest Information Update: 13 Feb 2007
Price :
$50
*
At a glance
- Originator Asterand plc
- Class Prostaglandins
- Mechanism of Action Dinoprostone agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dysmenorrhoea; Glaucoma; Preterm labour
Most Recent Events
- 13 Feb 2007 Discontinued - Preclinical for Dysmenorrhoea in United Kingdom (Intrauterine)
- 13 Feb 2007 Discontinued - Preclinical for Glaucoma in United Kingdom (Ophthalmic)
- 13 Feb 2007 Discontinued - Preclinical for Preterm labour in United Kingdom (Intrauterine)